EN
Why CareDx Stock Soared Today
Key Points
CareDx is a leader in the fast-growing field of medical diagnostics.
The company is working to bring its non-invasive tests to new markets.
Shares of CareDx (NASDAQ:CDNA) rose more than 22% on Friday after the medical diagnostics provider reported impressive growth metrics.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Testing volumes are soaring
CareDx's revenue surged 39% year over year to $139 million in the third quarter. The gains were driven by a 65% jump in testing services revenue to $119 million.
The healthcare specialist's testing volumes climbed 51% to 75,900, boosted by its acquisition of cancer blood-test maker Naveris in July.
"Clinicians want actionable precision molecular information about their patient's disease status and how it is changing over time to inform treatment decisions," CEO John Hanna said during a conference call with analysts.
Additionally, growth in CareDx's pharmacy services helped to drive a 31% increase in the company's patient and digital solutions revenue to $20 million.
All told, CareDx's earnings before interest, taxes, depreciation, and amortization (EBITDA) doubled to $30 million.
Interest in precision medicine diagnostics is rising
CareDx now sees full-year revenue growing by roughly 38% to $525 million in 2026. Management also raised its adjusted EBITDA target to $90 million to $100 million, up from a prior forecast of $66 million to $78 million.
"We see significant clinical interest in how molecular information can inform more decisions across a patient's care journey, while continuing to make our solutions easier for providers to adopt and patients to access," Hanna said. "We believe these dynamics create meaningful opportunities for continued profitable growth."
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.